Harvard Bioscience (HBIO) Market Capitalization (2010 - 2026)

Harvard Bioscience (HBIO) has reported Market Capitalization for 17 consecutive years, with $28.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Market Capitalization rose 42.89% year-over-year to $28.0 million in Q2 2026; TTM through Jun 2026 was $28.0 million, a 42.89% increase from a year earlier, with the FY2025 full-year figure at $30.0 million, down 67.78% from the prior year.
• Market Capitalization was $28.0 million for Q2 2026 at Harvard Bioscience, up from $22.0 million in the prior quarter.
• Over five years, Market Capitalization peaked at $256.1 million in Q1 2022 and troughed at $19.6 million in Q2 2025.
• A 5-year average of $117.7 million and a median of $116.9 million in 2022 frame the typical range for Market Capitalization.
• Across the five-year window, Market Capitalization soared 99.17% in 2023 and tumbled 86.31% in 2025, its largest moves.
• Over 5 years, Market Capitalization stood at $116.6 million in 2022, then surged by 99.17% to $232.2 million in 2023, then plunged by 59.94% to $93.0 million in 2024, then sank by 67.78% to $30.0 million in 2025, then declined by 6.56% to $28.0 million in 2026.
• The last three Market Capitalization figures came in at $28.0 million (Q2 2026), $22.0 million (Q1 2026), and $30.0 million (Q4 2025), per Business Quant data.